Eel Herpes Vaccine Partnership


 

TIDMHML 
 
RNS Number : 5036M 
Henderson Morley PLC 
30 January 2009 
 
30 January 2009 
 
HENDERSON MORLEY PLC 
(AIM: HML) 
("Henderson Morley" or "the Company") 
 
Eel Herpes vaccine partnership 
 
The Board of Henderson Morley Plc, the AIM quoted biotechnology company, is 
pleased to announce a co-development agreement with UK Glass Eels Ltd, ("UK 
Glass Eels") to produce a vaccine against Eel Herpes. 
 
Under this agreement, a vaccine will be supplied to UK Glass Eels on a 
commercial basis, and UK Glass Eels will have non exclusive rights to distribute 
the vaccine on a worldwide basis. 
 
The vaccine is already in advanced stages of development. It will be 
administered to eels whilst at the glass eel phase of their life-cycle. It is 
expected that first revenues from this partnership will be received during 2009. 
 
Eel farming in the EU has suffered considerable stock losses due to a recently 
identified virus, Herpes Virus Anguilarum (Eel herpes virus). UK Glass Eels is 
one of Europe's largest suppliers of glass eels for the re-stocking of eel 
farms, supplying almost one third of the EU market. 
 
The co-development is as a direct result of Henderson Morley's expertise 
regarding other herpes virus infections in fish, as much of the technology and 
expertise applied in the other projects is applicable to the development of this 
vaccine. 
 
Proprietor of UK Glass Eels, Peter Wood FRCVS stated "We are very pleased to be 
collaborating on this project. The impact that Eel herpes virus has been making 
on the eel farming community is significant, with many farmers suffering 
considerable financial losses as a consequence. An effective vaccine for the 
prevention of this infection could offer a significant commercial benefit to the 
eel industry." 
 
Chairman Andrew Knight commented "UK Glass Eels is the European leader in the 
supply of fish to the eel farming industry. We are very pleased to be partners 
in this co-development especially as we expect it to be revenue generating in 
2009." 
 
=--ENDS--- 
 
 
ENQUIRIES: 
 
HENDERSON MORLEY PLC 0121 442 4600 
Andrew Knight, Chairman 
BISHOPSGATE COMMUNICATIONS LTD                           0207 562 
3350 
 (Public Relations) 
 Maxine Barnes 
 Nick Rome 
BREWIN DOLPHIN INVESTMENT BANKING                           0113 241 0126 
(Nominated Adviser) 
Neil Baldwin 
 
HYBRIDAN LLP                                                             0203 
159 5085 
(Broker) 
Claire Noyce/Stephen Austin 
 
 
Notes to Editors: 
 
Henderson Morley was founded in 1996 with the objective of developing its anti 
viral application (Ionic Contra Viral Therapy (ICVT). ICVT is the Lead Platform 
and has been developed in-house and HML wholly owns the patent IPR. 
 
Further information on Henderson Morley plc can be accessed through the 
Company's website at www.henderson-morley.com 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 SALBLMPTMMITBFL

Henderson Mrly. (LSE:HML)
過去株価チャート
から 6 2024 まで 7 2024